Back to Search Start Over

Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles.

Authors :
Yoon DY
Daniels MJ
Willcocks RJ
Triplett WT
Morales JF
Walter GA
Rooney WD
Vandenborne K
Kim S
Source :
Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2024 Dec; Vol. 51 (6), pp. 671-683. Date of Electronic Publication: 2024 Apr 12.
Publication Year :
2024

Abstract

The study aimed to provide quantitative information on the utilization of MRI transverse relaxation time constant (MRI-T <subscript>2</subscript> ) of leg muscles in DMD clinical trials by developing multivariate disease progression models of Duchenne muscular dystrophy (DMD) using 6-min walk distance (6MWD) and MRI-T <subscript>2</subscript> . Clinical data were collected from the prospective and longitudinal ImagingNMD study. Disease progression models were developed by a nonlinear mixed-effect modeling approach. Univariate models of 6MWD and MRI-T <subscript>2</subscript> of five muscles were developed separately. Age at assessment was the time metric. Multivariate models were developed by estimating the correlation of 6MWD and MRI-T <subscript>2</subscript> model variables. Full model estimation approach for covariate analysis and five-fold cross validation were conducted. Simulations were performed to compare the models and predict the covariate effects on the trajectories of 6MWD and MRI-T <subscript>2</subscript> . Sigmoid I <subscript>max</subscript> and E <subscript>max</subscript> models best captured the profiles of 6MWD and MRI-T <subscript>2</subscript> over age. Steroid use, baseline 6MWD, and baseline MRI-T <subscript>2</subscript> were significant covariates. The median age at which 6MWD is half of its maximum decrease in the five models was similar, while the median age at which MRI-T <subscript>2</subscript> is half of its maximum increase varied depending on the type of muscle. The models connecting 6MWD and MRI-T <subscript>2</subscript> successfully quantified how individual characteristics alter disease trajectories. The models demonstrate a plausible correlation between 6MWD and MRI-T <subscript>2</subscript> , supporting the use of MRI-T <subscript>2</subscript> . The developed models will guide drug developers in using the MRI-T <subscript>2</subscript> to most efficient use in DMD clinical trials.<br />Competing Interests: Declarations. Conflict of interests: The authors declared no competing interests for this work.<br /> (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1573-8744
Volume :
51
Issue :
6
Database :
MEDLINE
Journal :
Journal of pharmacokinetics and pharmacodynamics
Publication Type :
Academic Journal
Accession number :
38609673
Full Text :
https://doi.org/10.1007/s10928-024-09910-1